Advertisement

Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis

Published:November 29, 2017DOI:https://doi.org/10.1016/j.radonc.2017.11.009

      Abstract

      Background and purpose

      The optimal number of radiotherapy fractions is a relevant input for planning resource needs. An estimation of the total number of fractions by country and tumour site is assessed for 2012 and 2025.

      Methods

      European cancer incidence data by tumour site and country for 2012 and 2025 were extracted from the GLOBOCAN database. Incidence and stage data were introduced in the Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) model, producing an evidence-based proportion of incident cases with an indication for radiotherapy and fractions by indication. An indication was defined as a clinical situation in which radiotherapy was the treatment of choice.

      Results

      The total number of fractions if radiotherapy was given according to guidelines to all patients with an indication in Europe was estimated to be 30 million for 2012; with a forecasted increase of 16.1% by 2025, yet with differences by country and tumour. The average number of fractions per course was 17.6 with a small range of differences following stage at diagnosis. Among the treatments with radical intent the average was 24 fractions, while it decreased to 2.5 among palliative treatments.

      Discussion

      An increase in the total number of fractions is expected in many European countries in the coming years following the trends in cancer incidence. In planning radiotherapy resources, these increases should be balanced to the evolution towards hypofractionation, along with increased complexity and quality assurance.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Borras J.M.
        • Lievens Y.
        • Barton M.
        • et al.
        How many new cancer patients will require radiotherapy treatment by 2025? An ESTRO-HERO analysis.
        Radiother Oncol. 2016; 119: 5-11
        • Round C.
        • Mee T.
        • Kirkby N.F.
        • Cooper T.
        • Williams M.V.
        • Jena R.
        The Malthus programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level.
        Clin Oncol. 2013; 25: 538-545
        • Round C.
        • Williams M.V.
        • Mee T.
        • et al.
        Radiotherapy demand and activity in England 2006–2020.
        Clin Oncol. 2013; 25: 522-530
        • Dunscombe P.
        • Grau C.
        • Defourny N.
        • et al.
        Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey.
        Radiother Oncol. 2014; 112: 165-177
        • Atun R.
        • Jaffray D.A.
        • Barton M.B.
        • et al.
        Expanding global access to radiotherapy.
        Lancet Oncol. 2015; 16: 1153-1186
        • Defourny N.
        • Dunscombe P.
        • Perrier L.
        • Grau C.
        • Lievens Y.
        Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis.
        Radiother Oncol. 2016; 121: 468-474
        • Bentzen S.M.
        • Heeren G.
        • Cottier B.
        • et al.
        Towards evidence based guidelines for radiotherapy infrastructure and staffing needs in Europe. The ESTRO-QUARTS project.
        Radiother Oncol. 2005; 75: 355-365
        • Erridge S.C.
        • Featherstone C.
        • Chalmers R.
        • Campbell J.
        • Stockton D.
        • Black R.
        What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?.
        Eur J Cancer. 2007; 43: 1802-1809
        • Slotman B.J.
        • Vos P.H.
        Planning of radiotherapy capacity and productivity.
        Radiother Oncol. 2013; 106: 266-270
        • Barton M.
        • Jacob S.
        • Shafiq J.
        • et al.
        Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012.
        Radiother Oncol. 2014; 112: 140-144
        • Wong K.
        • Delaney G.
        • Barton M.B.
        Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand.
        Radiother Oncol. 2016; 119: 45-49
        • Borras J.M.
        • Barton M.
        • Grau C.
        • et al.
        The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO group.
        Radiother Oncol. 2015; 116: 45-507
        • Borras J.M.
        • Lievens Y.
        • Dunscombe P.
        • et al.
        The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis.
        Radiother Oncol. 2015; 116: 38-44
        • Wong K.
        • Delaney G.
        • Barton M.B.
        Estimation of the optimal number of radiotherapy fractions for breast cancer: a review of the evidence.
        Radiother Oncol. 2015; 116: 174-178
        • Ferlay J.
        • Steliarova-Foucher E.
        • Lortet-Tieulent J.
        • et al.
        Cancer incidence and mortality patterns in Europe: Estimates for 40 European countries in.
        Eur J Cancer. 2012; 49: 1374-1403
      1. Ferlay J, Soerjomataram I, Erwick M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and mortality worldwide: IARC Cancer Base n 11. Lyon: International Agency for Research on Cancer; 2013. [Available from http://globocan.iarc.fr, accessed on 10/8/2016].

        • Lievens Y.
        • De Schutter H.
        • Stellamans K.
        • Rosskamp M.
        • van Eycken L.
        Radiotherapy access in Belgium: How far are we from evidence based utilisation?.
        Eur J Cancer. 2017; 84: 102-113
        • Rubin G.
        • Berendsen A.
        • Crawford S.M.
        • et al.
        The expanding role of primary care in cancer control.
        Lancet Oncol. 2015; 12: 1231-1272
        • Weller D.
        • Vedsted P.
        • Rubin G.
        • et al.
        The Aarhus statement improving design and reporting studies on early cancer diagnosis.
        Br J Cancer. 2012; 106: 1262-1267
        • Barton M.B.
        • Allen J.
        • Delaney G.
        • et al.
        Patterns of retreatment by radiotherapy.
        Clin Oncol. 2014; 26: 611-618
        • Moller T.R.
        • Brorsson B.
        • Ceberg J.
        • et al.
        A prospective survey of radiotherapy practice in 2011 in Sweden.
        Acta Oncol. 2003; 42: 387-410
        • Lewis S.L.
        • Porceddu S.
        • Nakamura N.
        • et al.
        Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists.
        Am J Clin Oncol. 2017; 40: 418-422
        • Hardcastle J.D.
        • Chamberlain J.O.
        • Robinson M.H.
        • et al.
        Randomised controlled trial of faecal occult-blood screening for colorectal cancer.
        Lancet. 1996; 348: 1472-1477
        • Brunt A.M.
        • Wheatley D.
        • Yarnold J.
        • et al.
        Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
        Radiother Oncol. 2016; 120: 114-118
        • Monten C.
        • Lievens Y.
        • Olteanu L.A.M.
        • et al.
        Highly accelerated irradiation in 5 fractions (HAI-5): feasibility in elderly women with early or locally advanced breast cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 922-930
        • Postmus P.E.
        • Kerr K.M.
        • Oudkerk M.
        • et al.
        Early and locally advanced non-small-cell lung càncer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2017; 28: iv1-iv21
        • Dearnaley D.
        • Syndikus I.
        • Mossop H.
        • et al.
        Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
        Lancet Oncol. 2016; 17: 1047-1060
        • Palma D.
        • Visser O.
        • Lagerwaard F.J.
        • et al.
        Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis.
        J Clin Oncol. 2010; 28: 5153-5159
        • Grau C.
        • Defourny N.
        • Malicki J.
        • et al.
        Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.
        Radiother Oncol. 2014; 112: 155-164
        • Lievens Y.
        • Coffey M.
        • Defourny N.
        • et al.
        Radiotherapy staffing in the European countries: Final results of the ESTRO-HERO survey.
        Radiother Oncol. 2014; 112: 178-186